Telix Pharmaceuticals (ASX:TLX) Reports H1 2025 Financial Results
Telix Pharmaceuticals (ASX:TLX) reports a 63% revenue increase in H1 2025, emphasizing strong growth and strategic investments for future expansion.
Category: ASX-TLX
Telix Pharmaceuticals Limited
Telix Pharmaceuticals (ASX:TLX) Reports Strong H1 2025 Results
Telix Pharmaceuticals (ASX:TLX) reports a 63% revenue increase in H1 2025, maintaining strong financial and operational growth.
Telix Pharmaceuticals Limited (ASX:TLX) Reports $186M Q1 Revenue
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix®
Telix Pharmaceuticals (ASX:TLX) announces FDA approval for Gozellix®, expanding prostate cancer imaging access in the U.S.
Telix Pharmaceuticals Limited (ASX:TLX) Completes Acquisition of FAP-targeting Theranostic Candidates
Telix Pharmaceuticals (ASX:TLX) completes acquisition of FAP-targeting theranostic candidates, expanding its oncology pipeline.